Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Tecogen’s disclosures usually means wading through technical CHP diagrams and detailed emissions data. Investors want the revenue split between product sales and long-term service, or need to confirm when executives file Form 4 insider transactions before major project wins. This page maps every SEC release to the exact question you are asking—whether it’s backlog growth or R&D spending—so you no longer have to hunt through dense footnotes.
Type a phrase like “Tecogen quarterly earnings report 10-Q filing” or “Tecogen proxy statement executive compensation” and Stock Titan returns the document plus an AI-powered summary that highlights segment margins, new clean-energy incentives, and board pay packages. Real-time alerts push Tecogen Form 4 insider transactions the moment they hit EDGAR, letting you track executive stock moves without refreshing your browser. Need context? Our expert engine links related 8-Ks, turning “Tecogen 8-K material events explained” into a concise timeline of project awards, financing rounds, or patent milestones.
Because Tecogen’s business blends equipment sales with recurring service revenue, understanding cash-flow nuances is critical. Our coverage spans every form—from the “Tecogen annual report 10-K simplified” that dissects backlog trends, to bite-size analytics for each “Tecogen earnings report filing analysis.” Use AI plain-language explanations to compare quarter-over-quarter growth, monitor compliance with clean-air regulations, and flag subsidy disclosures. In short, this hub is your fastest route to understanding Tecogen SEC documents with AI—all filings, all the time, always current.
Tecogen Inc. (TGEN) reported Q3 2025 results. Revenue rose to $7,183,121 from $5,630,130 a year ago, led by Products ($2,983,795) with strong Chiller sales ($2,234,728). Gross profit was $2,183,566, but higher operating expenses drove a loss from operations of $2,100,704 and a net loss of $2,130,947 (basic and diluted EPS $(0.07)).
Nine‑month revenue reached $21,755,712 versus $16,544,014 in 2024, with a net loss of $4,254,974. Cash flow from operations was $(7,336,419) for the nine months. Balance sheet liquidity improved: cash and cash equivalents were $15,253,975, up from $5,405,233 at year‑end, aided by a July 21 follow‑on offering of 3,985,000 shares at $5.00 per share, yielding net proceeds of $18,105,100. Total liabilities declined to $16,146,907 from $20,966,721, and stockholders’ equity increased to $25,317,381.
Shares outstanding were 29,818,979 at September 30, 2025, and 29,846,479 as of November 13, 2025.
Tecogen Inc. (TGEN) filed an 8-K announcing Q3 2025 earnings materials. The company furnished a press release with earnings commentary for the three and nine months ended September 30, 2025, under Item 2.02.
It also furnished an investor presentation under Item 7.01 to accompany an earnings conference call. The materials are attached as Exhibit 99.1 (press release, dated November 12, 2025) and Exhibit 99.2 (earnings call presentation, dated November 13, 2025). The company states these exhibits are being furnished and are not deemed “filed” for purposes of Section 18, nor incorporated by reference except as expressly set forth.
Tecogen Inc. Schedule 13G/A: Tryfon Natsis and Despoina Pantopoulou report joint beneficial ownership of 460,300 shares of Tecogen common stock, representing 1.8% of the class based on 25,269,362 shares outstanding as of May 20, 2025. The reporting persons hold shared voting and dispositive power over all 460,300 shares and have no sole voting or dispositive power. Each reporting person is a citizen of Greece and lists a residence in Abu Dhabi. The filing includes a certification that the shares were not acquired to change or influence control of the issuer.
Tecogen Inc. reported consolidated revenues of $14.57 million for the six months ended June 30, 2025, up from $10.91 million a year earlier, driven by a large increase in Products revenue to $5.69 million (prior $1.61 million) while Services remained roughly steady at $8.21 million and Energy Production declined to $0.67 million.
Gross profit rose to $5.68 million and consolidated net loss improved to $2.13 million for the six months (loss attributable to Tecogen $2.12 million, $(0.08) per share basic), compared with larger losses a year earlier. Cash and cash equivalents declined to $1.64 million from $5.41 million at year-end and operating activities used $3.78 million of cash in the first half. Acquisition-related contingent consideration and related liabilities tied to the Aegis maintenance acquisition carry a fair-value liability of about $1.25 million. Subsequent to the period, the company completed a public offering raising approximately $18.16 million net proceeds to fund growth and working capital.
Tecogen Inc. furnished earnings materials related to the three- and six-month periods ended June 30, 2025. The company issued a press release containing earnings commentary and supplemental information, and it has attached that press release as Exhibit 99.1 to this Current Report. Separately, Tecogen is furnishing an investor slide deck to be presented online in connection with an earnings conference call; that deck is attached as Exhibit 99.2.
The filing clarifies these items are being furnished (not "filed") for purposes of the Exchange Act. The 8-K itself does not include detailed financial figures; interested parties should review Exhibits 99.1 and 99.2 for the underlying earnings metrics and commentary.
Form 4 snapshot: On 07/24/2025 Tecogen Inc. (TGEN) granted Director John M. Albertine 25,000 stock options at an exercise price of $8.35. The options vest 25 % per year, first exercisable 07/24/2026 and expiring 07/24/2035.
The award lifts Albertine’s directly held derivative position to 175,000 options. No purchases or sales of common shares were reported and no change was disclosed in non-derivative share ownership. The filing, signed 07/28/2025, appears to be a routine board compensation grant with no immediate cash flow or share-count impact.
SEC Form 4: On 07/28/2025 Tecogen (TGEN) disclosed that its General Counsel & Secretary, John K. Whiting IV, received new equity on 07/24/2025.
- Restricted stock award: 11,976 common shares granted at $0; Whiting’s direct common share holdings rise to 12,612.
- Stock options: 24,075 options with a $8.35 strike, vesting 25 % per year beginning 07/24/2026 and expiring 07/24/2035. Total option holdings increase to 424,075.
No shares were sold. The grants increase insider alignment but introduce a modest future dilution overhang of up to 24,075 shares if exercised.
FAQ
What is the current stock price of Tecogen (TGEN)?
What is the market cap of Tecogen (TGEN)?
